| 000 | 03221nam a2200409 i 4500 | ||
|---|---|---|---|
| 999 |
_c361302 _d361302 |
||
| 001 | 361302 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102121339.0 | ||
| 006 | a|||| o|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 008 | 211009s2021 si | o |||| 0|eng d | ||
| 020 | _a9789811618734 | ||
| 024 | 7 |
_a10.1007/978-981-16-1873-4 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC280.O8 _b2021 EB |
|
| 245 | 0 | 0 |
_aOvarian Cancer Biomarkers : _bMapping to Improve Outcomes _cedited by Khalid El Bairi |
| 250 | _aFirst edition 2021 | ||
| 264 | 1 |
_aSingapore _bSpringer International Publishing _c2021 |
|
| 300 |
_a1 recurso en línea (XV, 229 páginas) _b9 ilustraciones, 8 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aArchivo de texto _bPDF |
||
| 490 | 0 | _aBiomedical and Life Sciences (SpringerNature-11642) | |
| 490 | 0 | _aBiomedical and Life Sciences (R0) (SpringerNature-43708) | |
| 505 | 0 | _aChapter 1. General Overview of the Origins and Pathology of Ovarian Cancer -- Chapter 2_An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology -- Chapter 3_The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways and Predictive Biomarkers -- Chapter 4_Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes -- Chapter 5_The Emergence of Circulating Tumor DNA in the Management of Ovarian Cancer -- Chapter 6_Proteomic Biomarkers for Early Detection and Patients' Stratification in Ovarian Cancer -- Chapter 7_Cutting-edge Technologies and Ovarian Cancer. | |
| 520 | 3 | _aThis book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy. | |
| 988 | _aSpringer_BiomedLife_2021 | ||
| 650 | 7 |
_2embne _9225524 _aOvarios _xCáncer |
|
| 700 | 1 |
_aEl Bairi, Khalid _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9680906 |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9789811618727 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811618741 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811618758 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-16-1873-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b01/2022 _dz _eb _zSI |
||